Pertuzumab plus trastuzumab combined with chemotherapy has become a standard neoadjuvant therapy option for patients with high-risk human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). There is still not enough evidence for the efficacy and safety of neoadjuvant pertuzumab and trastuzumab plus chemotherapy in HER2-positive BC patients in China, both in clinical trials and real-world settings. This study aimed to assess the efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy in Chinese patients with HER2-positive BC in real-world clinical application.

Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study / Zhou, Meirong; Wang, Shouman; Wan, Nengbin; Yuan, Songlin; Hu, Xiongqiang; Zhou, Wei; Qing, Bohua; Liu, Mingwen; Sun, Weihua; Fan, Peizhi; Wang, Jianguo; Cao, Hong; Xu, Haifan; Dai, Bin; Tang, Peizhi; Qian, Liyuan; Zhao, Xi; Xiao, Jun; Zhou, Huaiying; Hu, Jinhui; Ding, Li; Tripodi, Domenico; Zdenkowski, Nicholas; O’Keefe, Thomas J.; Sanchez, Alejandro Martin; Chen, Li; Zhang, Ping; Xu, Feng. - In: ANNALS OF TRANSLATIONAL MEDICINE. - ISSN 2305-5839. - 10:24(2022), pp. 1387-1387. [10.21037/atm-22-6054]

Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study

Tripodi, Domenico
Membro del Collaboration Group
;
2022

Abstract

Pertuzumab plus trastuzumab combined with chemotherapy has become a standard neoadjuvant therapy option for patients with high-risk human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). There is still not enough evidence for the efficacy and safety of neoadjuvant pertuzumab and trastuzumab plus chemotherapy in HER2-positive BC patients in China, both in clinical trials and real-world settings. This study aimed to assess the efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy in Chinese patients with HER2-positive BC in real-world clinical application.
2022
Breast cancer (BC); neoadjuvant; trastuzumab; pertuzumab; real-world
01 Pubblicazione su rivista::01a Articolo in rivista
Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study / Zhou, Meirong; Wang, Shouman; Wan, Nengbin; Yuan, Songlin; Hu, Xiongqiang; Zhou, Wei; Qing, Bohua; Liu, Mingwen; Sun, Weihua; Fan, Peizhi; Wang, Jianguo; Cao, Hong; Xu, Haifan; Dai, Bin; Tang, Peizhi; Qian, Liyuan; Zhao, Xi; Xiao, Jun; Zhou, Huaiying; Hu, Jinhui; Ding, Li; Tripodi, Domenico; Zdenkowski, Nicholas; O’Keefe, Thomas J.; Sanchez, Alejandro Martin; Chen, Li; Zhang, Ping; Xu, Feng. - In: ANNALS OF TRANSLATIONAL MEDICINE. - ISSN 2305-5839. - 10:24(2022), pp. 1387-1387. [10.21037/atm-22-6054]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1664913
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 2
social impact